- Home
- TARA
as 07-26-2024 4:00pm EST
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Upcoming Earnings Alert:
Get ready for potential market movements as Protara Therapeutics Inc. TARA prepares to release earnings report on 01 Aug 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 63.6M | IPO Year: | N/A |
| Target Price: | $26.50 | AVG Volume (30 days): | 138.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $5.24 | Next Earning Date: | 08-01-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Protara Therapeutics Inc. (TARA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | TARA | 10% Owner | Jul 9 '24 | Sell | $2.40 | 15,000 | $36,051.00 | 60,000 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jul 9 '24 | Sell | $2.40 | 32,993 | $79,295.38 | 2,161,423 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jul 9 '24 | Sell | $2.31 | 5,000 | $11,540.00 | 75,000 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jul 9 '24 | Sell | $2.31 | 13,061 | $30,144.79 | 2,194,416 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jul 9 '24 | Sell | $2.21 | 2,500 | $5,534.50 | 80,000 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jul 9 '24 | Sell | $2.21 | 5,997 | $13,276.16 | 2,207,477 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jun 27 '24 | Sell | $2.07 | 5,000 | $10,374.00 | 85,000 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jun 27 '24 | Sell | $2.07 | 12,994 | $26,959.95 | 2,219,262 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jun 27 '24 | Sell | $2.26 | 12,471 | $28,160.77 | 90,000 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jun 27 '24 | Sell | $2.26 | 34,103 | $77,007.98 | 2,232,256 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jun 25 '24 | Sell | $2.26 | 6,225 | $14,056.67 | 102,471 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | Jun 25 '24 | Sell | $2.26 | 6,500 | $14,677.65 | 2,266,359 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 30 '24 | Sell | $2.90 | 5,824 | $16,894.84 | 108,696 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 30 '24 | Sell | $2.94 | 9,230 | $27,113.13 | 114,520 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 21 '24 | Sell | $3.06 | 31,200 | $95,337.84 | 2,282,159 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 21 '24 | Sell | $3.06 | 1,800 | $5,500.26 | 124,250 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 21 '24 | Sell | $3.02 | 9,300 | $28,095.30 | 2,272,859 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 21 '24 | Sell | $3.00 | 500 | $1,501.05 | 123,750 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 17 '24 | Sell | $3.33 | 47,250 | $157,252.73 | 2,333,044 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 17 '24 | Sell | $3.06 | 19,685 | $60,247.91 | 2,313,359 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 17 '24 | Sell | $3.33 | 2,750 | $9,152.28 | 127,250 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 17 '24 | Sell | $3.06 | 1,200 | $3,672.72 | 126,050 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 9 '24 | Sell | $3.09 | 30,600 | $94,526.46 | 2,531,994 | SEC Form 4 |
| Opaleye Management Inc. | TARA | 10% Owner | May 9 '24 | Sell | $3.11 | 151,700 | $472,424.14 | 2,380,294 | SEC Form 4 |
Latest Protara Therapeutics Inc. News
TARA Breaking Stock News: Dive into TARA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
GlobeNewswire
3 months ago
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
4 months ago
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
GlobeNewswire
4 months ago
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
GlobeNewswire
4 months ago
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
GlobeNewswire
4 months ago
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
5 months ago
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Compare TARA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TARA Protara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.